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representing a 10.5% and 17% relative difference respectively (6). The authors' Table 2 shows a marked difference between mean basal and mean apical strain in all groups of CA, markedly exceeding normal values.
It is possible that a looser definition, perhaps only comparing apical and basal strain, may still be highly specific for amyloidosis, yet with an increased sensitivity. This might be a simple and interesting line of investigation in the future.
The association of LGE with LS is intriguing. Initial reports of LGE suggested that amyloidosis had a distinct pattern of uptake characterized by a predominantly subendocardial, noncoronary distribution (7), but subsequently it became apparent that several patterns may be seen (8) . The presumption is that LGE in all these cases reflects expansion of the Despite being limited by only 3 cases, the clinicopathological findings are novel and add to our understanding of the strain gradient seen in amyloid cardiomyopathy. However, the hypothesis that regional differences in amyloid deposition are responsible for regional differences in LS may not be the full story because 1 of the 3 (Patient #1 in Figure 4B of Ternacle et al. [3] ) showed only a very weak correlation. Thus, the jury remains out as to whether amyloid burden is the primary cause of impaired LS or whether there may be a contribution from another factor, for example, microvascular dysfunction (12) .
Overall, the findings of this study present new findings in the pathophysiology of cardiac amyloidosis, while highlighting some of the difficulties in studying an uncommon disease with varying pathophysiology. We are now entering an era in which AL amyloidosis can be successfully treated and in which novel agents are in clinical trials for TTR amyloidosis.
Any advance in understanding in the mechanisms of cardiac dysfunction in amyloidosis is thus of great interest, as it allows us to better understand whether and how new therapies affect the heart in this previously universally fatal disease (13, 14) . 
